IE
KNSA icon

Israel Englander’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Israel Englander’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-10,000
Closed -$185K – 6806
2021
Q1 		$185K Buy
+10,000
New +$205K ﹤0.01% 5521

Other funds holding KNSA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM

Israel Englander's KNSA Position: Q2 2026 in Review

Israel Englander reduced its Kiniksa Pharmaceuticals (KNSA) stake by 83% in Q2 2026, selling an estimated $24.4M and leaving 93,364 shares worth $5.97M. The position accounts for ﹤0.01% of the portfolio, ranked #2817.

Israel Englander first reported a position in KNSA in Q2 2018 and has held it in 31 quarters since. The position peaked at $39.4M in Q3 2025. 266 funds tracked by Wall St. Rank hold KNSA as of Q2 2026.

  • Israel Englander held 93,364 shares of Kiniksa Pharmaceuticals worth $5.97M as of Q2 2026.
  • Israel Englander sold 471,056 Kiniksa Pharmaceuticals shares in Q2 2026, an estimated $24.4M.
  • Kiniksa Pharmaceuticals made up ﹤0.01% of Israel Englander's portfolio in Q2 2026, its #2817 holding.
  • Israel Englander first reported a position in Kiniksa Pharmaceuticals in Q2 2018 and has held it in 31 quarters since.
  • Israel Englander's Kiniksa Pharmaceuticals position peaked at $39.4M in Q3 2025.
  • 266 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.